RecruitingPhase 2Drug trialA Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaThis study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.